Evidence map›Paper›PMID 20709959›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2010

Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire.

Edwige Roy, Dieudonnée Togbe, Amy D Holdorf, Dmitry Trubetskoy, Sabrina Nabti, Günter Küblbeck, Alexandra Klevenz, Annette Kopp-Schneider, Frank Leithäuser, Peter Möller and 5 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05218434 phase1completednot on this mapstarted 2021, after this paper: background citation

A Randomised, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AX-158 Following Administration of Single and, Multiple Ascending Oral Doses and Food Effect Sub-study in Healthy Male Volunteers

TypeinterventionalSponsorArtax Biopharma IncRan2021 to 2022Enrolled64ConditionsAutoimmune DiseasesArmsAX-158
NCT05725057 phase1 / phase2completednot on this mapstarted 2023, after this paper: background citation

A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

TypeinterventionalSponsorArtax Biopharma IncRan2023 to 2024Enrolled31ConditionsPsoriasis, Plaque PsoriasisArmsAX-158, Placebo
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. SLAMF7 (CD319) on activated CD8Cell death and differentiation · 2025
    Article
  3. Review
  4. Article
  5. Nck adaptors at a glance.Journal of cell science · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Evolution of SH2 domains and phosphotyrosine signalling networks.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012
    Review
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 5 countries.

Edwige RoyInstitut National de la Santé et de la Recherche Médicale, Institut Curie, 75005 Paris, France.
Dieudonnée Togbe
Amy D Holdorf
Dmitry Trubetskoy
Sabrina Nabti
Günter Küblbeck
Alexandra Klevenz
Annette Kopp-Schneider
Frank Leithäuser
Peter Möller
Friedhelm Bladt
Günter Hämmerling
Bernd Arnold
Tony Pawson
Anna Tafuri
DKFZ-ZMBH Alliance · DEInstitut Curie · FRGerman Cancer Research Center · DEUniversity Hospital Ulm · DEUniversity of Toronto · CACancer Research And Biostatistics · USInserm · FRLunenfeld-Tanenbaum Research Institute · CA

Funding

Canadian Institutes of Health Research MOP-13466Canadian Institutes of Health Research MOP-6849
6 · The paper itself

Abstract

The size and sensitivity of the T-cell repertoire governs the effectiveness of immune responses against invading pathogens. Both are modulated by T-cell receptor (TCR) activity through molecular mechanisms, which remain unclear. Here, we provide genetic evidence that the SH2/SH3 domain containing proteins Nck lower the threshold of T-cell responsiveness. The hallmarks of Nck deletion were T-cell lymphopenia and hyporeactivity to TCR-mediated stimulation. In the absence of the Nck adaptors, peripheral T cells expressing a TCR with low avidity for self-antigens were strongly reduced, whereas an overall impairment of T-cell activation by weak antigenic stimulation was observed. Mechanistically, Nck deletion resulted in a significant decrease in calcium mobilization and ERK phosphorylation upon TCR engagement. Taken together, our findings unveil a crucial role for the Nck adaptors in shaping the T-cell repertoire to ensure maximal antigenic coverage and optimal T cell excitability.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBlotting, WesternCalciumCell ProliferationCells, CulturedDendritic CellsFemaleFlow CytometryLymphopeniaMaleMiceMice, Inbred C57BLMice, KnockoutMicroscopy, FluorescenceMitogen-Activated Protein Kinase 1Adaptor Proteins, Signal TransducingCalciumMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Nck proteinOncogene ProteinsReceptors, Antigen, T-Cell

Identifiers

PMID20709959
PMCPMC2932578
OpenAlexW2143302096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.